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Objective: This study examines short-term mechanical assist device support for
cardiac transplant patients and compares their outcomes with nontransplant patients
requiring similar support.
Methods: Of 350 cardiac transplant patients at our institution, 7 patients required
mechanical ventricular assistance with the Abiomed BVS5000 assist device
(Abiomed, Inc, Danvers, Mass) after transplant secondary to severe acute rejection
with cardiogenic shock (n  4) or primary graft failure (n  3). Recovery of
ventricular function, survival to discharge, and complications were determined for
the transplant group and compared with a second group comprising all other patients
supported with the BVS5000 at our institution (n  15). Additionally, the results of
prior series reporting mechanical ventricular support of the failing transplant heart
are reviewed.
Results: Demographics and duration of support were similar between the groups.
The transplant group had a higher wean rate from device relative to the nontrans-
plant group (100% versus 13%; P  0.01). Five of 7 in the transplant group
achieved survival to discharge (71%), relative to 5 of 15 in the nontransplant group
(33%). Complications between the two groups were similar, although the transplant
group experienced a higher rate of renal insufficiency (57% versus 13%, P  0.05).
Conclusion: Severe acute rejection with cardiogenic shock and primary graft failure
are two conditions that may warrant mechanical ventricular support in the cardiac
transplant patient. Transplant patients with these conditions have a high rate of
ventricular functional recovery, greater than nontransplant patients supported with
the same device and for a similar period of time. Although the incidence of renal
insufficiency was higher, the majority of transplant patients who were supported
with the BVS5000 achieved survival to discharge.
Mechanical ventricular support is infrequently required for re-cipients of cardiac transplantation. However, two conditionsmay necessitate mechanical ventricular support for the trans-planted heart: severe acute rejection with cardiogenic shockand primary graft failure. After initial encouraging reports,more recent studies of mechanical ventricular assistance for
these conditions have described relatively poor outcomes.1-7 A variety of devices
have been utilized for ventricular support of these patients ranging from extracor-
poreal membrane oxygenation (ECMO) to more permanent ventricular assist de-
vices such as the Thoratec device (Thoratec Corporation, Pleasanton, Calif).
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We now have supported 7 cardiac transplant patients
with the Abiomed BVS5000 assist device (Abiomed, Inc,
Danvers, Mass). We chose this device due to its ease of
implantation and maintenance. This review illustrates the
implantation technique of the BVS5000 for cardiac trans-
plant patients. Additionally, the rates of ventricular recovery
and survival to discharge for these cardiac transplant pa-
tients are compared with a group of 15 nontransplant pa-
tients who were supported with the BVS5000 for other
indications at our institution. Given the concomitant immu-
nosuppression in the transplant patients, we also compared
postimplantation complications between the two groups.
Finally, we reviewed the literature for other reports of
cardiac transplant recipients requiring ventricular assist de-
vice (VAD) support.
Methods
Patient Groups
We identified all orthotopic cardiac transplant patients at our
institution (n  350) and reviewed the medical records of the 7
patients who required posttransplant support with the Abiomed
BVS5000 device. These 7 patients composed group A and either
suffered primary graft dysfunction at the time of implantation or
experienced severe acute rejection, which failed to improve after
inotropic support (Table 1).
Results in this cohort were compared with all other patients at
our institution who required ventricular support with the BVS5000
(n  15). These patients, who comprise group B, had low cardiac
output syndrome secondary to (1) post–cardiac surgery cardio-
genic shock, (2) acute viral myocarditis, or (3) cardiomyopathy
(Table 1).
All patients showed evidence of a low cardiac output state
(cardiac index  2.0 L/min/m2) despite volume optimization and
maximal pharmacologic support (dobutamine 25 to 30 mcg/kg/
min, epinephrine 0.8 to 1.2 mcg/kg/min, milrinone 0.50 to 0.75
mcg/kg/min). The vast majority of patients were supported with
intra-aortic balloon pumps (IABP; 6/7 in the transplant group,
14/15 in the nontransplant group) prior to BVS5000 implantation.
Abiomed BVS5000 support was started only after these less inva-
sive treatments failed to achieve viable hemodynamics.
For those transplant patients with biopsy-proven rejection,
high-dose methylprednisolone (Solu-Medrol), increased doses of
cyclosporine, and antilymphocyte antibodies were utilized. In ad-
dition, humoral rejection was treated aggressively with cyclophos-
phamide (Cytoxan), intravenous immunoglobin (IVIG), and plas-
mapheresis. In cases of primary graft failure, plasmapheresis was
utilized until biopsy and crossmatch results returned negative for
rejection and an immunologic process was ruled out as the etiology
of ventricular dysfunction.
For the two transplant patients who experienced primary graft
failure necessitating right ventricular assist device (RVAD) sup-
TABLE 1. Brief description for each patient in this study
Age/gender Indication Type of support Weaned Outcome
Group A
53 M Primary graft dysfunction BiVAD Yes Sepsis/death
51 M Primary graft dysfunction RVAD Yes Survival to discharge
60 M Primary graft dysfunction RVAD Yes Survival to discharge
67 F Severe acute rejection BiVAD Yes Survival to discharge
42 M Severe acute rejection BiVAD Yes Survival to discharge
45 F Severe acute rejection BiVAD Yes Stroke/death
30 F Severe acute rejection BiVAD Yes Survival to discharge
Group B
72 M Post–cardiac surgery shock BiVAD Yes Survival to discharge
32 F Post–cardiac surgery shock BiVAD Yes Mediastinitis/sepsis/death
58 F Post–cardiac surgery shock RVAD No Ventricular failure/death
49 F Post–cardiac surgery shock BiVAD No Stroke/death
54 M Post–cardiac surgery shock LVAD No Transplanted/survival to discharge
55 M Post–cardiac surgery shock BiVAD No Transplanted/sepsis/death
74 F Post–cardiac surgery shock BiVAD No Ventricular failure/death
75 M Post–cardiac surgery shock RVAD No Ventricular failure/death
37 F Acute viral myocarditis BiVAD No Transplanted/death
31 F Acute viral myocarditis BiVAD No Transplanted/survival to discharge
50 F Cardiomyopathy/arrest BiVAD No Transplanted/survival to discharge
52 M Cardiomyopathy/arrest BiVAD No Transplanted/survival to discharge
47 M Cardiomyopathy/arrest BiVAD No Transplanted/death
64 M Cardiomyopathy/arrest BiVAD No Stroke/death
52 M Cardiomyopathy/arrest BiVAD No Stroke/death
Group A patients were supported with the BVS5000 after cardiac transplantation. All of these patients were weaned from the device after left ventricular
recovery. Five of the 7 patients were long-term survivors. Group B comprises all other patients supported with the BVS5000; only 2 were weaned from the
BVS5000. Only 1 of these 2 patients survived to discharge. Four other patients who were unable to be weaned underwent subsequent heart transplant with
long-term survival. RVAD, Right ventricular assist device; LVAD, left ventricular assist device; BiVAD, biventricular assist device.
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port, both had less severe left ventricular (LV) dysfunction that
ultimately did not require ventricular assist device (VAD) support.
In both of these cases inhaled nitric oxide was utilized and failed
to achieve viable hemodynamics prior to RVAD placement. Ele-
vated pulmonary vascular resistance was not felt to be the primary
etiology for right ventricular (RV) failure.
Definitions
Weaned is defined as return of native ventricular function enabling
discontinuation of the device. Survival to discharge is defined as
survival enabling discharge from the hospital but excluding pa-
tients who expired after discharge due to complications from the
admission during which the device was implanted. (One patient
was discharged but within 5 days required readmission secondary
to renal failure and subsequently expired during rehospitalization.)
Survival 6 months after BVS5000 removal is defined as patients
alive 6 months after the device was explanted. No patients were
lost to follow-up. Patient age, wean status, duration of support,
survival to discharge, survival 6 months after BVS5000 removal,
and complications were recorded for each group.
Complications examined for each group included renal insuf-
ficiency, pulmonary insufficiency, stroke, bleeding, and sepsis.
Renal insufficiency is defined as more than a doubling of serum
creatinine during the period of BVS5000 support. Pulmonary
insufficiency is defined as the need for mechanical ventilation with
a FiO2  60% for more than 24 hours during the period of
BVS5000 support. Stroke is defined as any acute focal lesion
identified by computed tomography of the brain and/or a new focal
deficit identified on physical examination that occurred during the
period of BVS5000 support. Postoperative bleeding is reported as
the total amount of chest tube output during the first 24 hours after
device implantation. Sepsis is defined as positive blood cultures
during the period of BVS5000 support or wound infection extend-
ing to the sternal closure at any time following BVS5000 implan-
tation.
Surgical Technique
For all 7 transplant patients (group A), atrial cannulation was
employed and outflow graft cannulae were sewn onto the trans-
planted heart great vessels. The graft cannulae were sewn in an
end-to-side manner to the great vessels (aorta and/or pulmonary
artery) of the donor heart. The cannulae therefore were placed just
distal to the aortic or pulmonic valves and just proximal to the
transplant anastomoses (Figure 1). For the aortic anastomosis a
side-biting clamp was employed, while vacuum-assisted venous
drainage enabled an open anastomosis at the pulmonary artery (the
pulmonary artery is sufficiently decompressed that clamping is not
required). Others have described placement of the RVAD outflow
cannula through the right ventricle and then out through the
pulmonary valve.8 Our experience with this approach resulted in
problematic bleeding around the cannula. Additionally, cannula
placement through the right ventricle may be damaging to the right
ventricle itself. For these reasons we advocate use of the graft
cannula that is sewn easily to the pulmonary artery.
All heart transplants were implanted with a bicaval technique.
Therefore, an extensive area of recipient left atrium is present for
cannulation adjacent to the right pulmonary veins. We have found
left atrial cannulation in this location to be easier in the transplant
setting relative to other patients due to the extensive cuff of
recipient left atrium. Individual superior and inferior vena caval
anastomoses enabled cannulation of the donor heart right atrium
without interfering with suture lines (Figure 1).
Literature Review
A review of the literature was performed by electronic Medline
search utilizing the key words heart transplantation and heart-
assist device, incorporating journal articles published between
1966 and 2002. Case reports of individual patients were not
included.
Statistical Analysis
Student t test was used to compare age, gender, duration of
support, and postoperative bleeding between the two groups. Fis-
cher’s exact test was used to compare number weaned, survival to
discharge, 6-month survival after BVS5000 removal, renal insuf-
ficiency, pulmonary insufficiency, stroke, and sepsis between the
two groups. A P value  0.05 was considered statistically signif-
icant.
Figure 1. A heart transplant is illustrated and a bicaval implant
technique employed. For RVAD support, the body of the right
atrium is cannulated away from the superior and inferior vena
caval anastomoses. Outflow from the RVAD is to a graft cannula
sewn to the main pulmonary artery (PA). The graft is placed just
distal to the pulmonary valve but proximal to the anastomosis
between the donor and recipient PA. For LVAD support, the
recipient left atrial cuff is cannulated adjacent to the right pul-
monary vein, providing drainage to the pump. Outflow from the
LVAD is to a graft cannula sewn to the recipient aorta just above
the aortic valve. RVAD, Right ventricular assist device; LVAD, left
ventricular assist device.
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Results
Seven of 350 patients who had undergone cardiac transplant
required mechanical ventricular support with the BVS5000.
Three of the 7 patients had primary graft failure. In 2 of
these 3, graft dysfunction was predominantly right-sided.
The remaining 4 patients who received a BVS5000 after
cardiac transplantation had severe acute rejection with car-
diogenic shock despite conventional treatments (volume
loading, inotropic support, etc). Of these 4 patients, two
suffered from rejection during the first week after their
transplant procedure and a humoral component was identi-
fied. The remaining 2 patients experienced an episode of
severe rejection more than 1 year after transplant. In these
final 2 cases, patient noncompliance with their immunosup-
pressive regimen was suspected, and the etiology was more
typical cellular rejection.
Patients in group A were supported for an average of 5.2
days and all 7 experienced ventricular recovery enabling the
device to be weaned (Table 2). One of the 7 patients
suffered anoxic brain injury secondary to cardiac arrest that
occurred prior to device implantation. This patient died after
withdrawal of ventilatory support following graft ventricu-
lar recovery. Another patient developed sepsis and profound
leukopenia after device removal; multiorgan system failure
and death ensued. Concomitant immunosuppression con-
tributed to the complicating leukopenia in this case. The
remaining 5 patients each survived to discharge and were
alive at follow-up 6 months after device removal.
Group B, the nontransplant group, was comprised of 15
patients with 3 etiologies of ventricular failure: (1) post–
cardiac surgery shock, (2) acute viral myocarditis, or (3)
cardiomyopathy with sudden deterioration and cardiac ar-
rest. In contrast to group A, group B experienced a much
lower rate of weaning from device (P  0.01). Only 2
patients were weaned from the device in group B (13%).
Only 1 of the 15 patients was successfully weaned from the
device and survived to discharge (6%). Although there were
4 others who survived to discharge in group B, each of these
patients underwent cardiac transplantation after their native
ventricle failed to recover. The 5 patients in group B who
survived to discharge were alive at follow-up 6 months after
device removal.
No statistically significant differences were noted be-
tween the 2 groups with regard to age, gender, length of
support, survival to discharge, or survival 6 months after
BVS5000 removal (Table 2).
Complications for each group included stroke, pulmo-
nary insufficiency, renal insufficiency, sepsis, and postop-
erative bleeding (Table 3). Complications occurred at sim-
ilar rates in the two groups, but there was a greater incidence
of renal insufficiency in group A (P  .05). None of the
patients in either group required long-term renal dialysis.
No instances of device failure occurred in either group.
Discussion
Multiple studies have documented successful use of the
Abiomed BVS5000 device for patients who fail to wean
from cardiopulmonary bypass following conventional car-
diac surgery procedures.9-12 Indeed, post–cardiac surgery
cardiogenic shock or failure to wean from cardiopulmonary
bypass are the most common indications for this device in
previous series as well as among patients at our institution.
Use of the device in cardiac transplant patients has not been
extensively reviewed and presents new challenges. Preser-
vation of renal function may be more difficult given the
concomitant use of cyclosporine or tacrolimus. Further-
more, infectious complications that represent a major prob-
lem for VADs in general could pose even greater threats in
immunosuppressed cardiac transplant patients. Finally, the
capability of the transplanted heart to recover from severe
acute rejection with cardiogenic shock or after primary
failure of the graft has not been extensively studied. There-
fore, this report reviews our results when utilizing the
BVS5000 to support cardiac transplant patients.
Potential indications for BVS5000 ventricular support in
the cardiac transplant population are primary graft failure
and severe acute rejection with cardiogenic shock. Fortu-
nately, these conditions are uncommon.13 For primary graft
failure, early utilization of percutaneous IABP and inhaled
nitric oxide are advocated. These are important noninvasive
TABLE 2. Comparison of demographics/outcomes
Demographic/outcome Group A Group B P value
Age (in years) 49.5 53.4 .55
Duration of support (in days) 5.2 5.1 .86
Number weaned (%) 7/7 (100%) 2/15 (13%) .01
Survival to discharge (%) 5/7 (71%) 5/15 (33%) .36
Survival 6 months after BVS5000
removal
5/7 (71%) 5/15 (33%) .36
The number of patients weaned in Group A was significantly higher than
Group B (P .01). Survival to discharge and survival 6 months after device
removal, while not statistically significant, both trend toward Group A.
Additionally, 4 of the 5 patients in Group B who survived did not experience
native ventricular recovery, were unable to be weaned from the BVS5000,
and ultimately required orthotopic heart transplant. Age and duration of
support were not found to be statistically significant between the 2 groups.
TABLE 3. Comparison of complications
Complication Group A Group B P value
Postoperative bleeding
(mean in mL)
902 1076 .50
Renal insufficiency (%) 4/7 (57%) 2/15 (13%) .05
Pulmonary insufficiency (%) 1/7 (14%) 2/15 (13%) .95
Stroke (%) 1/7 (14%) 3/15 (20%) .29
Sepsis (%) 1/7 (14%) 2/15 (13%) .95
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measures that should be used before consideration of
BVS5000 implantation. For severe rejection cases, cellular
rejection was treated with high-dose methylprednisolone,
increased doses of cyclosporine, and antilymphocyte anti-
body preparations; in addition, potential humoral rejection
was treated with plasmapheresis, IVIG, and cyclophospha-
mide. For severe rejection, we again advocate percutaneous
IABP and inotropic support as less invasive initial treat-
ments. Nevertheless, multiple reports describe transplant
patients who require complete mechanical ventricular sup-
port. Table 4 summarizes reports of cardiac transplant pa-
tients who were completely supported with mechanical ven-
tricular assist devices.
In these previous reports, a variety of devices were used
including ECMO, centrifugal vortex pumps (Medtronic-
BioMedicus, Eden Prairie, Minn), intra-aortic axial flow
pumps, and Thoratec VADs. Again, primary graft failure
and severe acute rejection with cardiogenic shock comprise
the primary etiologies that necessitated mechanical support.
Despite the encouraging results of two small, early series in
the late 1980s, the results of recent reports generally have
not encouraged the use of mechanical support in the heart
transplant patient.1-7 Overall survival of these patients has
been poor, with substantial morbidity (Table 4).
The positive results in the transplant patients in this
study, relative to those seen in recent series, may be related
to the early systematic application of VAD support, as well
as to the type of VAD support. We have found the BVS5000
to be easy to implant, manage, and explant. Early systematic
application of the BVS5000 has avoided secondary compli-
cations that accompany circulatory failure.
Additionally, although there are only 7 patients in our
series, outcomes with the BVS5000 in cardiac transplant
patients appear better relative to other patients we have
supported with this device (Table 2). Notably, all the trans-
plant patients could be weaned from the device and all
experienced ventricular recovery. In contrast, among the
nontransplant group, only 13% were weaned and only 1
patient in this group experienced long-term survival with
the native heart. These results emphasize that the patho-
physiology instigating cardiogenic shock and the potential
for ventricular recovery are fundamentally different in these
2 groups. Results of the nontransplant patients demonstrate
the improved outcomes with the BVS5000 were not an
overall trend but may be limited to the transplanted hearts.
We advocate the BVS5000 because it can be rapidly
installed in the transplanted heart, is easily managed, and
can be removed without need for cardiopulmonary bypass.
In contrast, IABP may not provide the complete ventricular
support needed during these conditions and certainly does
not provide significant right ventricular support, which is
often important in the transplanted heart. Biomedicus
pumps and ECMO circuits generally require continuous
supervision by a perfusionist and may include risks for
additional complications (for example, limb ischemia from
percutaneous femoral cannulation). Finally, more perma-
nent VADs often require ventricular cannulation, making
explantation more difficult. Such long-term support is usu-
ally not necessary and, additionally, these long-term devices
are limited by higher cost.
The high rate at which the BVS5000 could be weaned in
this series emphasizes the recoverability of ventricular func-
tion in the transplanted heart during primary graft failure or
severe acute rejection with cardiogenic shock. The trans-
planted hearts recovered better than hearts supported for
other nontransplant conditions such as postcardiotomy
shock or viral myocarditis. On the basis of these results, we
advocate consideration of a systematic early application of
the BVS5000 for cardiac transplant patients with either
primary graft failure or severe acute rejection with cardio-
genic shock. Ventricular function appears to recover in both
of these conditions. This report does identify a higher inci-
dence of renal insufficiency for the transplant group. This
may result from the concomitant use of the immunosuppres-
sant cyclosporine, which can cause renal insufficiency. No-
tably, none of the patients in the transplant group required
permanent dialysis. Surprisingly, other complications such
as sepsis were not increased in the transplant group. Finally,
despite increased renal insufficiency, the BVS5000 success-
fully supported the failing donor heart, allowing long-term
survival in a majority of transplanted patients.
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